Stock Trading CanaryHONG KONG · DIRECTORS' NOTICES
Alphamab Oncology - B
09966 · Healthcare · Biotechnology
Score
Not ranked: no net buying on the exchange by a director in the last 180 days.
Price vs insider buying
9966.HK · HKD● Purchase × Sale ◇ Public disclosure ▥ 15-day cluster ·
Circles and crosses mark trade dates; diamonds below the axis mark later public disclosures. The trade became public on its disclosure date. Prices are nearest-session closes, not insider execution prices. Marker sizes are not compared when values or currencies differ.
Insiders' buying price vs the latest close
Insiders paid 10.19 HKD a share on average (1 purchase line, 1 buyer, 2025-11-19 – 2025-11-19). The close on 2026-11-05 was 34.7% below that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Director trades on the exchange
Purchases and sales on the exchange in the last 12 months, as counted in the score.
| Trade date | Filed | Director | Held as | Trade | Shares | Price | Value |
|---|---|---|---|---|---|---|---|
| 2025-11-19 | 2025-11-24 | LIU YANG | Spouse or child | Bought | 115,000 | HK$10.19 | HK$1.2M |
Purchases not counted · 2
Director notices of a purchase that the score leaves out, and why.
| Trade date | Director | Why not counted | Shares |
|---|---|---|---|
| 2026-06-04 | LIU Yang | Held through a trust or jointly | 554,000 |
| 2026-06-04 | XU TING | Held through a trust or jointly | 554,000 |